Catalog No. A10547

LY294002 is a PI3k inhibitor (cell IC50 about 10 μM) and a casein kinase II inhibitor.
  • Daniel Limonta, .et al. Fibroblast growth factor 2 enhances Zika virus infection in human fetal brain, J Infect Dis, 2019, 2019 PMID: 30799482
  • Lv H, .et al. CXCL8 gene silencing promotes neuroglial cells activation while inhibiting neuroinflammation through the PI3K/Akt/NF-κB-signaling pathway in mice with ischemic stroke, J Cell Physiol, 2018, Oct 26 PMID: 30362547
  • Hui Liang, .et al. Targeting the PI3K/AKT pathway via GLI1 inhibition enhanced the drug sensitivity of acute myeloid leukemia cells, Sci Rep, 2017, 7: 40361 PMID: 28098170
Catalog Num A10547
M. Wt 307.3
Formula C19H17NO3
Purity >98%
Storage at -20 °C 3 years (powder form); at -20 °C 6 months (Solution base)
CAS No. 154447-36-6
LY294002 is a PI3k inhibitor (cell IC50 about 10 μM) and a casein kinase II inhibitor.
p110α (Cell-free assay) p110δ (Cell-free assay) p110β (Cell-free assay)
0.5 μM0.57 μM0.97 μM
In vitro (25°C) DMSO 31 mg/mL (100.86 mM)
Water Insoluble
Ethanol 18 mg/mL (58.56 mM)
In vivo 5% DMSO+ 40%PEG 300+5% Tween 80+50%ddH2O 2 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 32.54 mL 162.71 mL 325.41 mL
0.5 mM 6.51 mL 32.54 mL 65.08 mL
1 mM 3.25 mL 16.27 mL 32.54 mL
5 mM 0.65 mL 3.25 mL 6.51 mL

*The above data is based on the productmolecular weight 307.3. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.